29 m⁶A-RNA Methylation (Epitranscriptomic) Regulators Are Regulated in 41 Diseases including Atherosclerosis and Tumors Potentially via ROS Regulation – 102 Transcriptomic Dataset Analyses

Figure 9

The m⁶A-RNA methylation regulators (m⁶A-RMRs) were differentially expressed in 18 cell populations of cancers in the Oncomine database (https://www.oncomine.org/). (a) The numbers in red were the numbers of m⁶A-RMRs upregulated, and the numbers in blue were the numbers of m⁶A-RMRs downregulated. The results showed that m⁶A-RMRs upregulated were more than m⁶A methylation regulators downregulated. The “Significant Unique Analyses” indicated the numbers of studies in which the analyzed genes were significantly upregulated (red) or downregulated (blue). The “Total Unique Analysis” indicated the numbers of studies in which the analyzed genes were included (, ) (METTL16, YTHDC1, and PRRC2A not found). (b) Different expression patterns of m⁶A-RMRs in different cell populations of cancers. The bar graph showed differential expression m⁶A regulators IGF2BP2 (upregulated in ten cancers, downregulated in three cancers, and uncertain in three cancers), IGF2BP3, and G3BP1 are the top 3 genes involved in different cancers. (c) IGF2BP3, G3BP1, and IGF2BP2/HNRNPC were upregulated in 12, 11, and 10 cancers, respectively. (d) ZC3H13, IGF2BP1, and WTAP/FTO/YTHDC2 were downregulated in six, five, and four cancers, respectively. (e) The expression of G3BP2 in five cancers was uncertain; WTAP, PCIF1, HNRNPA2B1, EIF3A, and IGF2BP2 in three cancers were uncertain.

(a)

(b)

(c)

(d)

(e)